Articles producció científica> Medicina i Cirurgia

Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study.

  • Datos identificativos

    Identificador: PC:515
    Autores:
    Holmes, M.V.Simon, T.Exeter, H.JFolkersen, L.Asselbergs, F.W.Guardiola, M.Cooper, J.A.Palmen, J.Hubacek, J.A.Carruthers, K.F.Horne, B.D.Brunisholz, K.D.Mega, J.L.Van Iperen, E.P.Li, M.Leusink, M.Trompet, S.Verschuren, J.J.Hovingh, G.K.Dehghan, A.Nelson, C.P.Kotti, S.Danchin, N.Scholz, M.Haase, C.L.Rothenbacher, D.Swerdlow, D.I.Kuchenbaecker, K.B.Staines-Urias, E.Goel, A.Van 't Hooft, F.Gertow, K.De Faire, U.Panayiotou, A.G.Tremoli, E., Baldassarre, D.Veglia, F.Holdt, L.M.Beutner, F.Gansevoort. R.T.Navis, G.J.Mateo, L.I.Breitling, L.P.Brenner, H.Thiery, J.Dallmeier, D.Franco-Cereceda, A.Boer, J.M.Stephens, J.W.Hofker, M.H.Tedgui, A.Hofman, A.Uitterlinden, A.G.Adamkova, V.Pitha, J.Onland-Moret, N.C.Cramer, M.J.Nathoe, H.M.Spiering, W.Klungel, O.H.Kumari, M.Whincup, P.H.Morrow, D.A.Braund, P.S.Hall, A.S.Olsson, A.G.Doevendans, P.A.Trip, M.D.Tobin, M.D.Hamsten, A.Watkins, H.Koenig, W.Nicolaides, A.N.Teupser, D.Day, I.N.Carlquist, J.F.Gaunt, T.R.Ford, I.Sattar, N.Tsimikas, S.Schwartz, G.G.Lawlor, D.A.Morris, R.W.Sandhu, M.S.Poledne, R.Maitland-van der Zee, A.H.Khaw, K.T.Keating, B.J.Van der Harst, P.Price, J.F.Mehta, S.R.Yusuf, S.Witteman, J.C.Franco, O.H.Jukema, J.W.De Knijff, P.Tybjaerg-Hansen, A.Rader, D.J.Farrall, M.Samani, N.J.Kivimaki, M.Fox, K.A.Humphries, S.E.Anderson, J.L.Boekholdt, S.M.Palmer, T.M.Eriksson, P.Paré, G.Hingorani, A.D.Sabatine, M.S.Mallat, Z.Casas, J.P.Talmud, P.J.
    Resumen:
    This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
  • Otros:

    Autor según el artículo: Holmes, M.V. Simon, T. Exeter, H.J Folkersen, L. Asselbergs, F.W. Guardiola, M. Cooper, J.A. Palmen, J. Hubacek, J.A. Carruthers, K.F. Horne, B.D. Brunisholz, K.D. Mega, J.L. Van Iperen, E.P. Li, M. Leusink, M. Trompet, S. Verschuren, J.J. Hovingh, G.K. Dehghan, A. Nelson, C.P. Kotti, S. Danchin, N. Scholz, M. Haase, C.L. Rothenbacher, D. Swerdlow, D.I. Kuchenbaecker, K.B. Staines-Urias, E. Goel, A. Van 't Hooft, F. Gertow, K. De Faire, U. Panayiotou, A.G. Tremoli, E., Baldassarre, D. Veglia, F. Holdt, L.M. Beutner, F. Gansevoort. R.T. Navis, G.J. Mateo, L.I. Breitling, L.P. Brenner, H. Thiery, J. Dallmeier, D. Franco-Cereceda, A. Boer, J.M. Stephens, J.W. Hofker, M.H. Tedgui, A. Hofman, A. Uitterlinden, A.G. Adamkova, V. Pitha, J. Onland-Moret, N.C. Cramer, M.J. Nathoe, H.M. Spiering, W. Klungel, O.H. Kumari, M. Whincup, P.H. Morrow, D.A. Braund, P.S. Hall, A.S. Olsson, A.G. Doevendans, P.A. Trip, M.D. Tobin, M.D. Hamsten, A. Watkins, H. Koenig, W. Nicolaides, A.N. Teupser, D. Day, I.N. Carlquist, J.F. Gaunt, T.R. Ford, I. Sattar, N. Tsimikas, S. Schwartz, G.G. Lawlor, D.A. Morris, R.W. Sandhu, M.S. Poledne, R. Maitland-van der Zee, A.H. Khaw, K.T. Keating, B.J. Van der Harst, P. Price, J.F. Mehta, S.R. Yusuf, S. Witteman, J.C. Franco, O.H. Jukema, J.W. De Knijff, P. Tybjaerg-Hansen, A. Rader, D.J. Farrall, M. Samani, N.J. Kivimaki, M. Fox, K.A. Humphries, S.E. Anderson, J.L. Boekholdt, S.M. Palmer, T.M. Eriksson, P. Paré, G. Hingorani, A.D. Sabatine, M.S. Mallat, Z. Casas, J.P. Talmud, P.J.
    Departamento: Medicina i Cirurgia
    e-ISSN: 1558-3597
    Autor/es de la URV: Guardiola, M. Michael V Holmes, Lasse Folkersen, Tabassome Simon
    Palabras clave: Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
    Resumen: This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0735-1097
    Página final: 1976
    Volumen de revista: 62
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S0735109713027782?via%3Dihub
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: https://doi.org/10.1016/j.jacc.2013.06.044
    Entidad: Universitat Rovira i Virgili.
    Año de publicación de la revista: 2013
    Página inicial: 1966
  • Palabras clave:

    Sistema cardiovascular--Malalties
    Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
    0735-1097
  • Documentos:

  • Cerca a google

    Search to google scholar